The White House says the Trump Administration's Most-Favored-Nation (MFN) drug pricing policy framework to address the major differences in drug prices and contributions to the pharmaceutical innovation enterprise across developed countries is expected to generate $529 billion in domestic savings in the next 10 years across all markets.
The Trump Administration has so far reached voluntary MFN pricing agreements with 17 of the largest pharmaceutical manufacturers in the world to lower prescription drug prices that Americans pay for some of the world's most innovative drugs, in line with the lowest prices paid by other developed nations, known as the most-favored-nation, or MFN, price.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.